| Omalizumab is approved for self-administration; however, guidance to identify suitable patients is lacking. |
| We provide practical considerations for the health care provider treating patients with omalizumab. |
| Considerations include ability of patient/caregiver to identity and treat anaphylaxis, patient empowerment, personal attributes, comorbid conditions, and potential impact of quality of life. |
| Shared decision-making between the health care provider and the patient is essential. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.